Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o#Actuate #Therapeutics #Presents #Topline #Elraglusib #Phase #Data #ASCO #Annual #Meeting #Trial #Meets #Primary #Endpoint #Median #Survival #Doubles #1Year #Survival #FirstLine #Treatment